📰 Allogeneic News
Allogeneic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.
January 9, 2024
(Article 223-16 of General Regulation of the French financial markets authority)...
December 5, 2023
A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.
November 29, 2023
Learn about the successful adult allogeneic bone marrow transplant performed at Zulekha Yenepoya Institute of Oncology. Find out how a 40-year-old man with relapsed acute myeloid leukaemia underwent a haploidentical transplant and recovered with minimal complications.
August 8, 2023
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser...
June 16, 2023
78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data...
June 9, 2023
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and... | June 9, 2023
June 9, 2023
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
June 7, 2023
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and... | June 7, 2023
June 5, 2023
Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that members of management... | June 5, 2023
June 5, 2023
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today presented long-term follow up... | June 5, 2023